{"cursor":"4544","size":15,"audio":[],"currentlang":"en","article":"{{Infobox company\n| name = SemBioSys Genetics Inc. logo = type = Public genre = foundation =\n| founder = location_city = Calgary, Alberta location_country = Canada location\n| = locations = area_served = key_people = James Szarko, President and CEO\n| industry = Biotechnology products = services = revenue = operating_income =\n| net_income = assets = equity = owner = num_employees = Approximately 20 parent\n| = divisions = subsid = homepage = [http://www.sembiosys.com www.sembiosys.com]\n| footnotes = intl =\n}} 'SemBioSys Genetics Inc.' was a development stage agricultural biotechnology\ncompany. It utilized its patented safflower pharming platform to develop and\nmake proteins and oils for the nutraceutical, functional food and beverage, and\npharmaceutical industries. A University of Calgary spin-off (1994), SemBioSys\nbecame a publicly traded firm. Investors had included Bay City Capital, the\nBusiness Development Bank of Canada, Dow AgroSciences (a Canadian subsidiary of\nThe Dow Chemical Company), Royal Bank Ventures Inc. (now RBC Capital Partners),\nthe University of Calgary, Ventures West Capital Ltd., and Dr. Maurice Moloney.\nIn May 2012, SemBioSys terminated its operations. [http://www.newswire.ca/en/story/975453/sembiosys-\nannounces-first-quarter-results-and-provides-update-on-activities Press release\nMay 15, 2012: SemBioSys Announces First Quarter Results and Provides Update on\nActivities]\n\nThe company's strategy was to partner with other companies to enable the\ncommercialization of products. Its lead pharmaceutical products under\ndevelopment were biosimilar insulin and Apo AI(Milano). In a phase I/II clinical\ntrial, SemBioSys demonstrated that its safflower produced insulin (SBS-1000) is\nbioequivalent to Humulin(R), a commercially available insulin. The Pharma\nLetter. 30 March 2009. [http://www.thepharmaletter.com/file/87226/plant-derived-insulin-passes-first-\nhuman-study.html Plant-derived insulin passes first human study]\n\nIn 2007, SemBioSys formed a subsidiary, Botaneco Specialty Ingredients Inc.,\ndedicated to the commercialization of SemBioSysâ products for cosmetic, personal\ncare and prescription topical dermatology products. Botaneco produced, marketed,\nand sold its products under the brand name Hydresia. In October 2009, Botaneco\nmerged with Quebec Ciy-based Advitech, a health sciences and technology company.\n\nIn October 2011, SemBioSys signed a collaboration agreement with Tasly\nPharmaceuticals, Ltd. [http://investing.businessweek.com/research/stocks/pr-\nivate/snapshot.asp?privcapId=183562323 Bloomberg BusinessWeek Profile] of\nTianjin, China and its wholly owned subsidiary Tasly U.S. [Press Release |\nhttp://micro.newswire.ca/release.cgi?rkey=1910112827&view=36078-\n0&Start=&htm=0] Tasly is of Chinaâs top five largest producers of\ntraditional Chinese medicines\n(TCMs). [http://www.taslyint.com/show.aspx?id=394&cid=6 Tasly Export\nStatement] Upon government approval, a new company called Tasly-SemBioSys\nBio-Pharmaceuticals Co., Ltd. was incorporated in Tianjin, China. The new\ncompany was structured as a Sino-Foreign Equity Joint Venture and seeks to\ndevelop and commercialize a variety of products including pharmaceutical,\nfunctional foods, and nutraceuticals for China and the world. However SemBioSys\ndid not transfer any intellectual property to the joint venture [http://www-\n.stockhouse.com/bullboards/messagedetailthread.aspx?p=0&m=30901194&l=0&r=0&s=SB-\nS&t=list SenBioSys News Release 2012-04-04 07:31 ET] Quote: \"This partnership\nhas not resulted in any financial benefit to SemBioSys to date and, as a result,\nthe company has not transferred any intellectual property to the newly formed\njoint venture as of this date.\" and Tasly terminated the agreement.\n","linknr":118,"url":"SemBioSys_Genetics","recorded":1362503903,"links":10,"instances":["genetics"],"pdf":[],"categories":["Biotechnology companies of Canada"],"headings":["See also","References","External links"],"image":["//bits.wikimedia.org/static-1.21wmf10/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf10/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["pharming","genetics"]],"members":["pharming"],"related":["Public_company","Calgary,_Alberta","Canada","Agricultural","Biotechnology","Safflower","Pharming_(genetics)","Proteins","Oils","Nutraceutical","Functional_food","Functional_beverage","Pharmaceutical","University_of_Calgary","Business_Development_Bank_of_Canada","Dow_AgroSciences","Dow_Chemical_Company","Insulin","ApoA-1_Milano","Humulin","Personal_care","Traditional_Chinese_medicines","Tianjin","Nutraceuticals","Plant-made_pharmaceuticals"]}